Role of EZH2 in epithelial ovarian cancer: From biological insights to therapeutic target

Frontiers in Oncology

Volumn 3 MAR, Issue , 2013, Pages

  Li, Hua ^a   Zhang, Rugang ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

Epigenetic therapeutics; Epithelial ovarian cancer; EZH2; EZH2 inhibitors; PRC2

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 1; EPZ 005687; GSK 126; HISTONE METHYLTRANSFERASE; METHYLTRANSFERASE; POLYCOMB REPRESSIVE COMPLEX 2; S ADENOSYLMETHIONINE; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; B CELL LYMPHOMA; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; FOLLICULAR LYMPHOMA; GENE SILENCING; HUMAN; LOSS OF FUNCTION MUTATION; NONHUMAN; OVARY CARCINOMA; PROTEIN EXPRESSION; SHORT SURVEY; TUMOR MICROENVIRONMENT;

EID: 84890584944     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00047     Document Type: Short Survey

References (52)

1. Agger, K., Cloos, P. A., Christensen, J., Pasini, D., Rose, S., Rappsilber, J., et al. (2007). UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 449, 731-734.
2. Altomare, D. A., Wang, H. Q., Skele, K. L., De Rienzo, A., Klein-Szanto, A. J., Godwin, A. K., et al. (2004). AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23, 5853-5857.
3. American Cancer Society. (2012). Cancer Facts & Figures 2012. Atlanta: American Cancer Society.
4. Ballare, C., Lange, M., Lapinaite, A., Martin, G. M., Morey, L., Pascual, G., et al. (2012). Phf19 links methylated Lys36 of histone H3 to regulation of Polycomb activity. Nat. Struct. Mol. Biol. 19, 1257-1265.
5. Bodor, C., O'Riain, C., Wrench, D., Matthews, J., Iyengar, S., Tayyib, H., et al. (2011). EZH2 Y641 mutations in follicular lymphoma. Leukemia 25, 726-729.
6. Bracken, A. P., Dietrich, N., Pasini, D., Hansen, K. H., and Helin, K. (2006). Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 20, 1123-1136.
7. Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., et al. (2011). Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365, 2473-2483.
8. Cao, R., and Zhang, Y. (2004). SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol. Cell 15, 57-67.
9. Cha, T. L., Zhou, B. P., Xia, W., Wu, Y., Yang, C. C., Chen, C. T., et al. (2005). Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 310, 306-310.
10. Chen, S., Bohrer, L. R., Rai, A. N., Pan, Y., Gan, L., Zhou, X., et al. (2010). Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat. Cell Biol. 12, 1108-1114.
11. Dawson, M. A., and Kouzarides, T. (2012). Cancer epigenetics: from mechanism to therapy. Cell 150, 12-27.
12. Gui, Y., Guo, G., Huang, Y., Hu, X., Tang, A., Gao, S., et al. (2011). Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat. Genet. 43, 875-878.
13. Guil, S., Soler, M., Portela, A., Carrere, J., Fonalleras, E., Gomez, A., et al. (2012). Intronic RNAs mediate EZH2 regulation of epigenetic targets. Nat. Struct. Mol. Biol. 19, 664-670.
14. Hu, S., Yu, L., Li, Z., Shen, Y., Wang, J., Cai, J., et al. (2010). Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol. Ther. 10, 788-795.
15. Jaenisch, R., and Young, R. (2008). Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell 132, 567-582.
16. Jankowska, A. M., Makishima, H., Tiu, R. V., Szpurka, H., Huang, Y., Traina, F., et al. (2011). Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 118, 3932-3941.
17. Jones, P. A., and Baylin, S. B. (2007). The epigenomics of cancer. Cell 128, 683-692.
18. Ketel, C. S., Andersen, E. F., Vargas, M. L., Suh, J., Strome, S., and Simon, J. A. (2005). Subunit contributions to histone methyltransferase activities of fly and worm polycomb group complexes. Mol. Cell. Biol. 25, 6857-6868.
19. Kleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., et al. (2003). EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 100, 11606-11611.
20. Knutson, S. K., Wigle, T. J., Warholic, N. M., Sneeringer, C. J., Allain, C. J., Klaus, C. R., et al. (2012). A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 8, 890-896.
21. Kuhn, E., Kurman, R. J., and Shih, I. M. (2012). Ovarian cancer is an imported disease: fact or fiction? Curr. Obstet. Gynecol. Rep. 1, 1-9.
22. Kurman, R. J., and Shih, I. M. (2010). The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am. J. Surg. Pathol. 34, 433-443.
23. Landeira, D., Sauer, S., Poot, R., Dvorkina, M., Mazzarella, L., Jorgensen, H. F., et al. (2010). Jarid2 is a PRC2 component in embryonic stem cells required for multi-lineage differentiation and recruitment of PRC1 and RNA Polymerase II to developmental regulators. Nat. Cell Biol. 12, 618-624.
24. Lee, J. M., Lee, J. S., Kim, H., Kim, K., Park, H., Kim, J. Y., et al. (2012). EZH2 generates a methyl degron that is recognized by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex. Mol. Cell 48, 572-586.
25. Levanon, K., Crum, C., and Drapkin, R. (2008). New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J. Clin. Oncol. 26, 5284-5293.
26. Li, H., Bitler, B. G., Vathipadiekal, V., Maradeo, M. E., Slifker, M., Creasy, C. L., et al. (2012a). ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches. Cancer Prev. Res. (Phila.) 5, 484-491.
27. Li, H., Cai, Q., Wu, H., Vathipadiekal, V., Dobbin, Z. C., Li, T., et al. (2012b). SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK. Mol. Cancer Res. 10, 1462-1472.
28. Li, H., Cai, Q., Godwin, A. K., and Zhang, R. (2010). Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Mol. Cancer Res. 8, 1610-1618.
29. Lu, C., Han, H. D., Mangala, L. S., Ali-Fehmi, R., Newton, C. S., Ozbun, L., et al. (2010). Regulation of tumor angiogenesis by EZH2. Cancer Cell 18, 185-197.
30. Majer, C. R., Jin, L., Scott, M. P., Knutson, S. K., Kuntz, K. W., Keilhack, H., et al. (2012). A687V EZH2 is a gain-of-function mutation found in lymphoma patients. FEBS Lett. 586, 3448-3451.
31. McCabe, M. T., Graves, A. P., Ganji, G., Diaz, E., Halsey, W. S., Jiang, Y., et al. (2012a). Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc. Natl. Acad. Sci. U.S.A. 109, 2989-2994.
32. McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., et al. (2012b). EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108-112.
33. Miranda, T. B., Cortez, C. C., Yoo, C. B., Liang, G., Abe, M., Kelly, T. K., et al. (2009). DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol. Cancer Ther. 8, 1579-1588.
34. Morin, R. D., Johnson, N. A., Severson, T. M., Mungall, A. J., An, J., Goya, R., et al. (2010). Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 181-185.
35. Nakamura, M., Shimada, K., and Konishi, N. (2008). The role of HRK gene in human cancer. Oncogene 27(Suppl. 1), S105-S113.
36. Palacios, D., Mozzetta, C., Consalvi, S., Caretti, G., Saccone, V., Proserpio, V., et al. (2010). TNF/p38alpha/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. Cell Stem Cell 7, 455-469.
37. Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., et al. (2011). A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365, 2484-2496.
38. Qi, W., Chan, H., Teng, L., Li, L., Chuai, S., Zhang, R., et al. (2012). Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc. Natl. Acad. Sci. U.S.A. 109, 21360-21365.
39. Rao, Z. Y., Cai, M. Y., Yang, G. F., He, L. R., Mai, S. J., Hua, W. F., et al. (2010). EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis 31, 1576-1583.
40. Rizzo, S., Hersey, J. M., Mellor, P., Dai, W., Santos-Silva, A., Liber, D., et al. (2011). Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol. Cancer Ther. 10, 325-335.
41. Ryan, R. J., Nitta, M., Borger, D., Zukerberg, L. R., Ferry, J. A., Harris, N. L., et al. (2011). EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. PLoS ONE 6:e28585. doi:10.1371/journal.pone.0028585
42. Schwartz, Y. B., and Pirrotta, V. (2007). Polycomb silencing mechanisms and the management of genomic programmes. Nat. Rev. Genet. 8, 9-22.
43. Sneeringer, C. J., Scott, M. P., Kuntz, K. W., Knutson, S. K., Pollock, R. M., Richon, V. M., et al. (2010). Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl. Acad. Sci. U.S.A. 107, 20980-20985.
44. Su, I. H., Dobenecker, M. W., Dickinson, E., Oser, M., Basavaraj, A., Marqueron, R., et al. (2005). Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell 121, 425-436.
45. Tan, J., Yang, X., Zhuang, L., Jiang, X., Chen, W., Lee, P. L., et al. (2007). Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21, 1050-1063.
46. Ting, A. H., McGarvey, K. M., and Baylin, S. B. (2006). The cancer epigenome-components and functional correlates. Genes Dev. 20, 3215-3231.
47. Tsai, M. C., Manor, O., Wan, Y., Mosammaparast, N., Wang, J. K., Lan, F., et al. (2010). Long noncoding RNA as modular scaffold of histone modification complexes. Science 329, 689-693.
48. Van der Vlag, J., and Otte, A. P. (1999). Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat. Genet. 23, 474-478.
49. Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., et al. (2002). The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624-629.
50. Wei, Y., Xia, W., Zhang, Z., Liu, J., Wang, H., Adsay, N. V., et al. (2008). Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol. Carcinog. 47, 701-706.
51. Xu, K., Wu, Z. J., Groner, A. C., and He, H. H. (2012). EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent. Science 338, 1465-1469.
52. Zhao, J., Sun, B. K., Erwin, J. A., Song, J. J., and Lee, J. T. (2008). Polycomb proteins targeted by a short repeat RNA to the mouse X chromosome. Science 322, 750-756.